SeekingAlphaAugust 9, 2026 at 11:51 PM NY25 days ago
Corvus: Strong Buy Soquelitinib Q1 2027 Interim Futility Analysis And AD Drug Advancement
Corvus Pharma (CRVS) Strong Buy: soquelitinib PTCL & atopic dermatitis catalysts, key 2027 readouts, $215M cash to Q2 2028âread now.
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site — SeekingAlpha
Companies in This Story
Related Stories
The trading volume of these stocks is deviating from the norm in today's session.
ChartMill2 hours ago
Discover which S&P500 stocks are making waves on Friday.
ChartMill2 hours ago
Sodexo : Monthly disclosure on share capital and voting rights August 31, 2026
Yahoo3 hours ago
ANF vs. TPR: Which Stock Is the Better Value Option?
Yahoo3 hours ago
Anthropic's IPO Push Just Got a $15 Billion Backstop
Yahoo3 hours ago